Ceritinib: first global approval

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that can drive cancer when abnormally fused with other proteins.
• ALK rearrangements are key drivers in a subset of non-small cell lung cancer (NSCLC).
• Targeted therapies inhibiting ALK have transformed treatment paradigms for ALK-positive NSCLC.

Purpose of the Study:

• To summarize the development milestones of ceritinib.
• To highlight the first approval of ceritinib for specific NSCLC patients.
• To provide an overview of ceritinib's role in ALK-positive NSCLC treatment.

Main Methods:

• Review of clinical development data for ceritinib.
• Summary of regulatory submissions and approvals.
• Analysis of ceritinib's efficacy in patients with ALK-positive metastatic NSCLC.

Main Results:

• Ceritinib received US FDA approval as a second-line treatment for ALK-positive metastatic NSCLC.
• The drug is indicated for patients who have progressed on or are intolerant to crizotinib.
• Phase III trials are evaluating ceritinib in first- and second-line settings.

Conclusions:

• Ceritinib represents a significant advancement in the treatment of ALK-positive NSCLC.
• The drug offers a crucial therapeutic option for patients with limited alternatives.
• Ongoing research aims to further define ceritinib's role in NSCLC management.